LabCorp Announces Appointment of Chief Financial Officer

  LabCorp Announces Appointment of Chief Financial Officer

 Glenn A. Eisenberg Appointed as Executive Vice President and Chief Financial
                       Officer Effective June 16, 2014

Business Wire

BURLINGTON, N.C. -- March 25, 2014

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) today
announced the appointment ofGlennA.EisenbergasExecutive Vice President
and Chief Financial Officer, effectiveJune 16, 2014. Brad Hayes will continue
in his role as Chief Financial Officer through the transition to

“I am delighted thatGlennwill be joining us as Chief Financial
Officer,”said David P. King, Chairman and Chief Executive Officer. “He is a
seasoned financial executive with a track record of strategic leadership in
both financial and operational roles. His appointment underscoresour
continued focus on disciplined financial management and forward looking,
innovative thinking about the evolution of our business. We are excited to
have Glenn join the executive management team and we look forward to his
contributions to the execution of our five pillar strategy.”

Mr. Eisenbergmost recently served as the Executive Vice President, Finance
and Administrationand Chief Financial Officerat The Timken Company(NYSE:
TKR), a $4.3 billion leading global manufacturer of highly engineered bearings
and alloy steels and related products and services. Previously, heserved as
President and Chief Operating Officerof United Dominion Industries, now a
subsidiary of SPX Corporation (NYSE: SPW)after working in several roles in
finance, including Executive Vice President and Chief Financial Officer
ofUnited Dominion. Mr. Eisenberg serves on the boards of directors of Family
Dollar Stores Inc. (NYSE: FDO), where he chairs the Audit Committee, andAlpha
Natural Resources Inc. (NYSE: ANR), where he is the lead independent director
and chairs the Nominating and Corporate Governance Committee.

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its LabCorp Specialty Testing
Group: The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon
Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark
Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials
testing through its LabCorp Clinical Trials division. LabCorp clients include
physicians, government agencies, managed care organizations, hospitals,
clinical labs, and pharmaceutical companies. To learn more about our
organization, visit our website at:

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payers. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2013.


Laboratory Corporation of America^® Holdings
Investor/Media Contact:
Stephen Anderson, 336-436-5076
Company Information:
Press spacebar to pause and continue. Press esc to stop.